bDMARD switches | Rheumatoid arthritis (n=2290) | Psoriatic arthritis (n=1097) | Ankylosing spondylitis (n=948) |
---|---|---|---|
From anti-TNF to non-anti-TNF (%) | 719 (31) | 448 (41) | 315 (33) |
From one anti-TNF to another anti-TNF (%) | 738 (32) | 351 (32) | 514 (54) |
From a non-anti-TNF to an anti-TNF (%) | 486 (21) | 167 (15) | 118 (12) |
From non-anti-TNF to another non-anti-TNF (%) | 347 (15) | 131 (12) | 1 (0.1) |
Non-anti-TNF bDMARDs include: Abatacept, Anakinra, Rituximab, Tocilizumab, Secukinumab, Ustekinumab.
bDMARD, biologic disease modifying anti-rheumatic drugs; TNF, tumour necrosis factor.